Key result
This review compares the pharmacological actions and clinical trial evidence of phosphodiesterase type 5 inhibitors and soluble guanylate cyclase stimulators for pulmonary arterial hypertension.
Why the study?
Are phosphodiesterase type 5 inhibitors or sGC stimulators better for the treatment of pulmonary arterial hypertension?
Are phosphodiesterase type 5 inhibitors or sGC stimulators better for the treatment of pulmonary arterial hypertension?
This review compares the pharmacological actions and clinical trial evidence of PDE5 inhibitors and sGC stimulators to determine the optimal treatment strategy for pulmonary arterial hypertension.
Comparison of PDE5 inhibitors and sGC stimulators does not resolve optimal PAH therapy; leaves open need for direct comparative trials.
Pulmonary arterial hypertension is a chronic and life-threatening disease that if left untreated is fatal. Current therapies include stimulating the nitric oxide-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate axis, improving the prostacyclin pathway and inhibiting the endothelin pathway. Phosphodiesterase type 5 inhibitors, such as sildenafil, and the sGC stimulator riociguat are currently used in the treatment of pulmonary arterial hypertension. This article discusses the similarities and differences between phosphodiesterase type 5 inhibitors and sGC stimulator based on pharmacological action and clinical trials, and considers which is better for the treatment of pulmonary arterial hypertension.
No takes yet. Share an insight, caveat, or question.
Hiroshi Watanabe (2018) conducted a review in Pulmonary arterial hypertension. Phosphodiesterase type 5 inhibitors and sGC stimulators was evaluated. This review compares the pharmacological actions and clinical trial evidence of phosphodiesterase type 5 inhibitors and soluble guanylate cyclase stimulators for pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: